You just read:

Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Advanced Malignant Neuroendocrine Tumors at Annual Meeting of the Chinese Society of Clinical Oncology

News provided by

Innovent Biologics, Inc.

Sep 20, 2018, 22:45 ET